InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | 2026-03-25 | Angel Matthew | Director & CEO and President | Purchase | 231.5K | $2.16 | $500K | 231.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $12.6M-55.7% | $28.5M+62.7% | $17.5M-22.3% | $22.5M+31.2% | $17.2M |
| General and administrative | $14.0M+3.1% | $13.6M+16.2% | $11.7M-3.7% | $12.1M+23.4% | $9.8M |
| Operating loss | -$26.6M+36.8% | -$42.0M-44.1% | -$29.2M+15.8% | -$34.6M-28.4% | -$27.0M |
| Interest expense | -$207K+84.3% | -$1.3M+9.2% | -$1.4M+10.4% | -$1.6M-26.2% | -$1.3M |
| Interest income and other income (expense), net | $520K-65.3% | $1.5M+34.4% | $1.1M+103.1% | $549K+1714.7% | -$34K |
| Other income (expense), net | $313K+71.0% | $183K+154.8% | -$334K+68.8% | -$1.1M+18.8% | -$1.3M |
| Provision for income taxes | $0 | $0 | $0 | $0 | $0 |
| Net loss | -$26.3M+37.2% | -$41.8M-41.9% | -$29.5M+17.4% | -$35.7M-26.2% | -$28.3M |
| Net loss per share of common stock and pre-funded warrants, basic | -$6.33+67.5% | -$19.5-920.9% | -$1.91+38.2% | -$3.09+58.6% | -$7.47 |
| Net loss per share of common stock and pre-funded warrants, diluted | -$6.33+67.5% | -$19.5-920.9% | -$1.91+38.2% | -$3.09+58.6% | -$7.47 |
| Weighted-average shares used in computing basic net loss per share | $4.1M+93.3% | $2.1M-86.1% | $15.4M+33.5% | $11.5M+204.7% | $3.8M |
| Weighted-average shares of common stock and pre-funded warrants outstanding, diluted | $4.1M+93.3% | $2.1M-86.1% | $15.4M+33.5% | $11.5M+204.7% | $3.8M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
Tempest Therapeutics GAAP EPS of -$2.53
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting